It has been proven that using CXCR4 antagonists can alter the interaction between tumors and stroma, increase cancer cell sensitivity to cytotoxic drugs, and alleviate the burden of tumor growth and metastasis.Recently, researchers have identified a pro-inflammatory subset of MSCs (referred to as AIF1+CSF1R+MSCs) in rats with primary liver cancer (199). Here, CXCR4 is linked to neoplasm.